Pramlintide for the treatment of diabetes mellitus

Annals of Pharmacotherapy

Volumn 37, Issue 7-8, 2003, Pages 1082-1089

  Kleppinger, Erika L ^a   Vivian, Eva M ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Amylin; Diabetes mellitus; Postprandial hyperglycemia; Pramlintide

Indexed keywords

AMYLIN; GLUCOSE; INSULIN; PRAMLINTIDE;

ANOREXIA; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; FOOD INTAKE; GASTROINTESTINAL DISEASE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDLINE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; VOMITING;

EID: 0038102668     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C387     Document Type: Review

References (34)

1. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol & Ther 2002;4:175-89.
2. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724-30.
3. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharmaceut Design 2001;7:1353-73.
4. Amylin: a brief review of physiological functions. San Diego: Amylin Pharmaceuticals, June 2001.
5. Druger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetic Educator 1999;25:389-98.
6. Buse JB. Progressive use of medical therapies in type 2 diabetes. Diabetes Spectrum 2000;13:211-20.
7. DeFronzo R. Pharmacological therapy for type 2 diabetes. Ann Intern Med 1999;17:281-303.
8. Gerich JE. Matching treatment to pathophysiology in type 2 diabetes. Clin Ther 2000;23:646-59.
9. Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002;20:137-44.
10. Vella A, Lee JS, Camilleri M, Szarka LA, Burton DD, Zinsmeister AR, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 2002;14:123-31.
11. Schmitz O, Nyholm B, Orskov L, Gravholt C, Moller N. Effects of amylin and the amylin agonist pramlintide on glucose metabolism. Diabet Med 1997;14 (suppl 2):S19-23.
12. Beaumont K, Kenney MA, Young AA, Rink TJ. High affinity amylin binding sites in rat brain. Mol Pharmacol 1993;44:493-7.
13. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 1994;62:553-67.
14. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC. Amylin: a novel action in the brain to reduce body weight. Endocrinology 2000;141:850-3.
15. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G. Amylin: history and overview. Diabet Med 1997:14(suppl 2):S9-13.
16. Young AA. Amylin's physiology and its role in diabetes. Curr Op Endocrinol Diabetes 1997;4:282-90.
17. Thompson R, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM. Diabetes 1997;46:632-6.
18. Thompson RG, Pearson L, Kolterman OG. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with DDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia 1997;40:1278-85.
19. Thompson RG, Pearson L, Schoenfeld S, Kolterman OG. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. Diabetes Care 1998;21:987-93.
20. Nyholm B, Orskov L, Hove K, Gravholt CH, Moller N, Alberti GMM, et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 1999;48:935-41.
21. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type I diabetes intensively treated with insulin pumps. Diabetes Care 2003;26:1-8.
22. Gottlieb A, Velte M, Fineman M, Kolterman O. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks (abstract). Diabetes 2000;49(suppl 1):A109.
23. Fineman M, Bahner A, Gottlieb A, Kolterman OG. Effects of six months administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes (abstract). Diabetes 1999;48(suppl 1):A113.
24. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Techn Ther 2002;4:51-61.
25. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 2003;26:748-90.
26. Gottlieb A, Fineman M, Bahner A, Parker J, Walte G, Kolterman O. Pramlintide therapy in addition to insulin in type 2 diabetes: effect on metabolic control after 6 months (abstract). Diabetologia 1999;42(suppl 1):A232.
27. Fineman M, Maggs D, Burrell T, Velte M, Kolterman O. Addition of pramlintide to insulin therapy in type 1 diabetes: impact on glycemic and weight control stratified by BMI (abstract). Diabetes 2001;50(suppl 2):A112.
28. 1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets (abstract). Diabetologia 2002;45(suppl 2):A240.
29. Maggs DG, Burrell TA, Fineman MS, Kolterman OG. Pramlintide as adjunctive treatment to insulin in type 2 diabetes resulted in improved glycemic control and concomitant weight loss (abstract). Diabetes 2001;50(suppl 2):A124.
30. Borm AK, Klevesath MS, Borcea V, Kasperk C, Seibel MJ, Wahl P. et al. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm Metab Res 1999;31:472-5.
31. Roman D. Medical officer review Symlin NDA no 21-332. June 14, 2001. Division of Metabolic and Endocrine Drug Products. www.fda.gov/ohrms/dockets/ac/01/briefing/3761b1_03_Medical%20Review% 20Safety.pdf (accessed 2002 Oct 31).
32. Cook JC, Foletta MG. United States Securities and Exchange Commission Form 10-Q: Second quarterly report 2002. August 12, 2002. Amylin Pharmaceuticals, Inc. www.media.corporate-ir.net/media_files/NSD/AMLN/reports/q202_10q.pdf (accessed 2002 Sep 4).
33. Redalieu E, Thompson RG, Dean E, Petrella E, Musunuri S, Gottlieb A, et al. Pharmacokinetics of pramlintide and free insulin following combined or separate injections in patients with type 1 diabetes (abstract). Diabetes 1996;45(suppl 2):A220.
34. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med 1997;14:547-55.